Does LATANOPROSTENE BUNOD Cause Product packaging quantity issue? 8 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 8 reports of Product packaging quantity issue have been filed in association with LATANOPROSTENE BUNOD (Vyzulta). This represents 1.5% of all adverse event reports for LATANOPROSTENE BUNOD.
8
Reports of Product packaging quantity issue with LATANOPROSTENE BUNOD
1.5%
of all LATANOPROSTENE BUNOD reports
0
Deaths
0
Hospitalizations
How Dangerous Is Product packaging quantity issue From LATANOPROSTENE BUNOD?
Of the 8 reports.
Is Product packaging quantity issue Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LATANOPROSTENE BUNOD. However, 8 reports have been filed with the FAERS database.
What Other Side Effects Does LATANOPROSTENE BUNOD Cause?
Eye irritation (64)
Eye pain (56)
Ocular hyperaemia (56)
Intraocular pressure increased (43)
Drug ineffective (31)
Product quality issue (29)
Vision blurred (28)
Death (27)
Headache (22)
Instillation site pain (21)
What Other Drugs Cause Product packaging quantity issue?
LEUPROLIDE (523)
ALBUTEROL (431)
BUDESONIDE\FORMOTEROL (301)
FENTANYL (286)
BUPRENORPHINE (225)
CYCLOSPORINE (206)
ESTRADIOL (201)
BIMATOPROST (177)
RIVAROXABAN (174)
EXENATIDE (154)
Which LATANOPROSTENE BUNOD Alternatives Have Lower Product packaging quantity issue Risk?
LATANOPROSTENE BUNOD vs LATANOPROST\NETARSUDIL
LATANOPROSTENE BUNOD vs LATANOPROST\TIMOLOL
LATANOPROSTENE BUNOD vs LATISSE
LATANOPROSTENE BUNOD vs LATUDA
LATANOPROSTENE BUNOD vs LAZERTINIB